Pretreatment pulmonary tumor necrosis is a promising prognostic imaging biomarker for first-line anti-PD-1/PD-L1 therapy in advanced lung squamous cell carcinoma: a multi-institutional, propensity score-matching cohort analysis.
Qiaofeng ZhongLongfeng ZhangLin WuJun ZhaoJianguo SunYong FangJin ZhouQian ChuYihong ShenZhenzhou YangLijin ChenMeijuan HuangXiaoyan LinZhenhua LiuPeng ShenZhijie WangXin WangHuijuan WangCheng-Bo HanAnwen LiuHongmei ZhangFeng YeWen GaoFang WuZhengbo SongShengchi ChenChengzhi ZhouDingzhi HuangQiuyu ZhangXinlong ZhengXiaobin ZhengQian MiaoKan JiangZihua ZouYiquan XuShiwen WuHaibo WangYaping HongTao LuChao LiCheng HuangChuanben ChenGen LinPublished in: Therapeutic advances in medical oncology (2024)
Our study suggests that the presence of PTN on baseline contrast-enhanced chest CT is a potential negative prognostic imaging biomarker for the outcome of anti-PD-1/PD-L1 inhibitor therapy in advanced LSCC. Further studies are warranted to validate these findings and explore the underlying mechanisms.
Keyphrases
- contrast enhanced
- magnetic resonance imaging
- squamous cell carcinoma
- computed tomography
- diffusion weighted
- high resolution
- magnetic resonance
- dual energy
- diffusion weighted imaging
- image quality
- positron emission tomography
- radiation therapy
- mesenchymal stem cells
- stem cells
- human health
- fluorescence imaging
- smoking cessation